Page 1

BeyondSpring DUBLIN - 3 ( BPI - 2358-103 ) : A Global Phase 3 Trial with the Plinabulin / Docetaxel combination vs. Doc in 2nd / 3rd Line NSCLC Patients with EGFR - wild type Progressing on a Prior Platinum - Based Regimen ( NCT02504489 ) September 2021 | NASDAQ : BYSI